NCT02964689 - Binimetinib in Addition to Standard Chemotherapy in KRAS Mutated NSCLC. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 12, 2017

Primary Completion Date

July 2, 2021

Study Completion Date

July 2, 2021

Conditions

Advanced Non-small Cell Lung CancerKRAS Gene MutationLung Cancer

Interventions

DRUG

Binimetinib

Binimetinib will be administered in combination with pemetrexed and cisplatin (induction therapy), and with pemetrexed only (maintenance therapy), during the first 2 weeks of each cycle. Cycles will be repeated every 21 days.

DRUG

Pemetrexed

Pemetrexed 500 mg/m2 i.v. is applied on day 1 of each cycle, before cisplatin administration

DRUG

Cisplatin

Cisplatin 75 mg/m2 i.v. is applied on day 1 of each induction therapy cycle. The drug must be administered after pemetrexed infusion

Trial Locations (4)

4031

Universitaetsspital Basel, Basel

6500

IOSI Ospedale Regionale di Bellinzona e Valli, Bellinzona

9007

Kantonsspital St. Gallen, Sankt Gallen

CH-7000

Kantonsspital Graubuenden, Chur

All Listed Sponsors

lead

Swiss Cancer Institute

OTHER